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Abstract: Bone morphogenetic protein-2 (BMP-2) and fibroblast growth factor-2 (FGF-2) have been
regarded as the major cytokines promoting bone formation, however, several studies have reported
unexpected results with failure of bone formation or bone resorption of these growth factors. In this
study, BMP-2 and FGF-2 adsorbed into atellocollagen sponges were transplanted into bone defects in
the bone marrow-scarce calvaria (extramedullary environment) and bone marrow-abundant femur
(medullary environment) for analysis of their in vivo effects not only on osteoblasts, osteoclasts but
also on bone marrow cells. The results showed that BMP-2 induced high bone formation in the
bone marrow-scarce calvaria, but induced bone resorption in the bone marrow-abundant femurs.
On the other hand, FGF-2 showed opposite effects compared to those of BMP-2. Analysis of cellular
dynamics revealed numerous osteoblasts and osteoclasts present in the newly-formed bone induced
by BMP-2 in calvaria, but none were seen in either control or FGF-2-transplanted groups. On the
other hand, in the femur, numerous osteoclasts were observed in the vicinity of the BMP-2 pellet,
while a great number of osteoblasts were seen near the FGF-2 pellets or in the control group. Of note,
FCM analysis showed that both BMP-2 and FGF-2 administrated in the femur did not significantly
affect the hematopoietic cell population, indicating a relatively safe application of the two growth
factors. Together, these results indicate that BMP-2 could be suitable for application in extramedullary
bone regeneration, whereas FGF-2 could be suitable for application in medullary bone regeneration.
Keywords: BMP-2; FGF-2; bone formation; bone marrow
1. Introduction
Large bone defects caused, for instance, by tumor, trauma, or infection, induce substantial
functional impairment and consequent esthetic and psychological distress for the patients. Nevertheless,
reconstruction and regeneration of such large bone defects are yet a significant challenge in orthopedic
and oral and maxillofacial fields.
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Bone grafting is a surgical procedure that promotes the reconstruction of large bone defects with
materials, among which autogenous bone grafts have long been considered as the gold standard and
the most effective material [1,2]. However, autogenous bone grafts present significant drawbacks,
such as the risk of infection at the donor site and the restricted amount of harvestable bone [3,4].
Thus, a number of bone substitute materials have been developed to overcome the problems associated
with autogenous bone graft using cells (e.g., bone marrow-derived stem cells or adipose-derived stem
cells) or materials [e.g., collagen, β-tricalcium phosphate (β-TCP), hydroxyapatite (HA)] with/without a
combination of cytokines [e.g., fibroblast growth factors (FGFs), bone morphogenetic proteins (BMPs)
and platelet-derived growth factor (PDGF)] [5–8]. Among several cytokines, FGF-2 and BMP-2 are of
particular interest because they are currently widely utilized in periodontal surgery and spine fusion
or oral-maxillofacial surgery, respectively [9–12].
The FGF family is a group of multifunctional cytokines that regulate a number of complex
biological processes related to tissue development and homeostasis [13,14]. In bone, FGF signaling has
key roles in regulating osteogenesis and mineral homeostasis [14,15]. Among FGFs, FGF-2 is one of the
most effective cytokines that promote angiogenesis and osteogenesis and recruitment of mesenchymal
stem cells and osteoblasts [16].
BMPs are growth factors that belong to the transforming growth factor (TGF)-β superfamily and
have various functions in embryonic development and patterning, tissue homeostasis, and organ
regeneration [17–19]. Many of the BMPs are characterized by the ability to induce ectopic and orthotopic
bone formation [20–22], particularly, BMP-2 is well known to be a strong inducer of bone formation
and to play important roles in the development and regeneration of bone and cartilage [17,18,23].
In 2003, the US Food and Drug Administration (FDA) approved the application of recombinant human
BMP-2 (rhBMP-2) for the anterior lumbar interbody fusion, and currently, rhBMP-2 is widely used in
spine and oral-maxillofacial surgeries [9,10,12].
Together, rhFGF-2 and rhBMP-2 could be the major cytokines for application in regenerative
therapies of large bone defects [9–12]. However, an increasing number of studies have reported
complications, such as failure of bone regeneration and bone resorption, associated with the clinical
use of the two growth factors [24].
Recently, our research group also reported that rhBMP-2 transplanted in the bone
marrow-abundant environment induced bone resorption in a canine dental implant model [25].
On the other hand, Nagayasu et al. showed that bone formation was accelerated by the administration
of FGF-2 in the bone marrow environment [26]. From these reports, we hypothesized that the
bone-forming capabilities of FGF-2 and BMP-2 largely depend on the presence or absence of a bone
marrow environment at the recipient site, and that elucidation of the mechanisms of FGF-2 and BMP-2
functions at these different sites would be the key for not only the successful clinical treatments using
rhFGF-2 and rhBMP-2, but also the development of novel composite biomaterials that can optimize the
function of the two growth factors.
Therefore, the aim of this study was to evaluate the effect of FGF-2 and BMP-2 on bone regeneration
in both bone marrow scarce or abundant environments at the tissue level, as well as at the cellular
level, by investigating their effects on various cells present in the bone marrow, such as osteoblasts,
osteoclasts, mesenchymal cells, hematopoietic cells and endothelial cells. The results demonstrated
that BMP-2 promoted higher bone formation than FGF-2 in bone marrow-scarce calvaria, but the
opposite effect was observed in marrow-abundant femurs.
2. Results
2.1. BMP-2, but Not FGF-2, Promotes the Repair of Mouse Calvarial Defect
First, in order to investigate the ability of FGF-2 and BMP-2 to induce bone regeneration in the
bone marrow-scarce calvaria, freeze-dry atellocollagen pellets containing 1 or 10 µg of FGF-2 or 10 µg
of BMP-2 were transplanted into mouse calvarial bone defects. Because Charoenlarp et al. have
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reviewed that a microgram dose of FGF-2 could induce bone formation in rodents [16], concentrations
of 1 and 10 µg of FGF-2 were used in this study. On the other hand, since our previous analysis showed
that BMP-2 (1, 10, and 100 µg) dose-dependently enhanced bone formation in mouse calvarial and
inhibited bone formation in mouse femoral bone defects [25], a single dose of BMP-2 (10 µg) was used
in this study.
Quantitative analysis of the regenerated bone volume (RBV) using micro-CT showed that
10 µg of BMP-2 significantly induced bone formation compared with the control group, 14 days
after transplantation. However, bone formation was not observed in the groups transplanted with
1 µg and 10 µg of FGF-2 (Figure 1A,B). In accordance with the results of the micro-CT analysis,
histological investigations revealed the detailed aspect of the newly regenerated bone formed only in
the BMP-2-transplanted group at 14 days post-transplantation, but bone formation was not observed
in any group at 5 days post-transplantation (Figure 1C).
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Figure 1. BMP-2, but not FGF-2, promotes repair of mouse calvarial defect. Collagen pellets containing
BMP-2 (10 µg) or FGF-2 (1 µg, 10 µg) or distilled water (DW, control) were transplanted into mouse
calvarial defects. (A) Frontal section (upper panel) and 3D (lower panel) images of micro-CT, 14 days
after transplantation. (B) Graph shows the quantitative analysis of the regenerated bone volume (RBV)
(n = 3, *** p < 0.001 versus control pellet (#). One-way ANOVA/Tuk y). (C) HE-staining of frontal
sections at the defect ar a at 5 days and 14 days after surg ry. The results are representative of at least
three independent experiments. Lower panels are high magnification images of the squares in the
upper images. Two-way arrows, white arrowheads and black arrowheads indicate the bone defects,
newly-formed bone and calvarial bone, respectively.
Int. J. Mol. Sci. 2020, 21, 7967 4 of 14
2.2. FGF-2, but Not BMP-2, Promotes the Repair of Mouse Femoral Defect
Next, to examine the effects of FGF-2 and BMP-2 in the bone marrow-abundant environment,
pellets containing 1 or 10 µg of FGF-2 or 10 µg of BMP-2 were transplanted into mouse femoral
defects. Micro-CT analysis showed that the trabecular bone in the marrow was resorbed by BMP-2
administration, as reported previously [25]. Interestingly, however, FGF-2 significantly promoted bone
formation in the marrow in a dose-dependent manner (Figure 2A). The results of the quantitative
analysis confirmed the opposing effects of BMP-2 and FGF-2 in inducing bone formation in the marrow
environment (Figure 2B).
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Figure 2C shows the images of HE stained femurs after 5 and 14 days of transplantation. Although
bony areas were observed around the transplanted pellets in the control and BMP-2 groups at
5 days post-transplantation, no mature bone was observed around the BMP-2 pellets after 14 days of
transplantation. In the groups transplanted with FGF-2, bone formation was observed at the implanted
site both at 5 days and 14 days post-transplantation.
2.3. Depletion of Bone Marrow Cells Inhibits FGF-2-Induced Bone Formation in the Marrow Cavity
Previously, our group has reported that the number of marrow cells dramatically decreased when
the normal and the ablated femurs were subsequently transplanted into the back of recipient mice.
Interestingly, we also demonstrated that BMP-2 induced bone formation in inverse proportion to the
number of marrow cells in the bone marrow [25]. Therefore, in order to examine the relationship
between FGF-2-induced bone formation and marrow cells in the marrow cavity, bone marrow ablation
and transplantation experiments were performed. Contrarily to the result observed with BMP-2 [25],
the bone formation induced by FGF-2 was dramatically inhibited in the normal femurs and the
ablated femurs subsequently transplanted into the back of recipient mice (Figure 3). Taken together,
these results and our previous report strongly indicate that bone marrow cells play important roles in
the regulation of the activity of BMP-2 and FGF-2 in inducing bone formation.
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Figure 3. Depletion of bone marrow cells inhibits FGF-2-induced bone formation in the marrow cavity.
FGF-2-adsorbed collagen pellets were implanted in mouse femur defects in the following conditions: (#1)
Intact marrow (normal, control); (#2) Ablated marrow (ablation); (#3) Femur translocation; (#4) Marrow
ablation and femur translocation. (A) Sagittal section images of femur defect areas (left panel) and 3D
images of the trabecular bone (right panel). (B) Quantitative evaluation of BV/TV of trabecular bone in
femur defect area. (n = 4, *** p < 0.001 v rsus control pell t (#). One-way ANOVA/Tukey).
2.4. Effects of BMP-2 and FGF-2 on Osteoblast and Osteoclast in Mouse Calvarial and Femoral Defects
Col1a1(2.3)-GFP/Trap-tdTomato mice were used to understand the effects of BMP-2 and FGF-2 on
osteoblasts and osteoclasts in vivo, using the calvarial and femoral defects. In the bone marrow-scarce
calvaria, after 5 days of transplantation, BMP-2 promoted a re arkable migration of GFP-positive
osteoblasts to the transplanted site. After 14 days, tdTomato-positive osteoclasts were also observed
in the regenerated bone together with GFP-positive osteoblasts, indicating a remodeling of the
over-formed bone induced by BMP-2. On the other hand, since the calvarial defect does not heal
spontaneously, the two cell types were not observed in the control group and FGF-2 groups (Figure 4A).
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In the bone marrow-abundant femur, however, FGF-2 promoted bone formation by attracting
the GFP-positive osteoblasts to the healing site at 5 days post-transplantation. After 14 days,
both GFP-positive osteoblasts and tdTomato-positive osteoclasts, which would be involved in the bone
remodeling process, were observed at the transplanted site (Figure 4B). GFP-positive osteoblasts and
tdTomato-positive osteoclasts were also observed in the control group, because the repair of bone
defects in the femur occurs physiologically within 14 days. On the other hand, interestingly, in the
group transplanted with BMP-2, only tdTomato-positive osteoclasts were observed at the transplanted
site either at 5 days or 14 days post-transplantation.
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2.5. Effects of BMP-2 and FGF-2 on Angiogenesis in Mouse Calvarial and Femoral Defects
Angiogenesis is a key process in the early period of bone healing, and both FGF-2 and BMP-2
have been reported to promote angiogenesis [27–30]. Therefore, to evaluate the effects of BMP-2 and
FGF-2 on neovascularization in mouse calvarial and femoral defects, we performed IHC analysis for
the detection of endomucin (EMCN), which is specifically expressed in the vascular endothelial cells
of adult mice, and flow cytometric analysis (FCM) for detection of CD31+/CD45− endothelial cells.
The results showed that in the bone marrow-scarce calvaria, EMCN-positive endothelial cells were
observed at the transplanted site in all groups, but remarkably in the regenerated bone induced by
BMP-2, at 14 days post-transplantation (Figure 5A).
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Cross-sectional frozen sections of calvaria (frontal plane, A) and femurs (B) obtained from wild-type
mice after 5 and 14 days of collagen pellet implantation. EMCN-positive endothelial cells are shown in
purple. Dashed lines indicate the cortical bone (white) and the remained collagen pellet (*, yellow).
Nuclei were stained with DAPI (blue). The results are representative of at least three independent
experiments. Collagen pellets containing BMP-2 (10 µg) or FGF-2 (10 µg) or DW (control) were
transplanted into mouse femur defects and samples were analyzed by FCM (C) at 5 days and 14 days
after transplantation. Endothelial cell: CD31+CD45−. (n = 3–6, One-way ANOVA/Tukey).
Oppositely, in the bone marrow-abundant femur, the number of EMCN-positive endothelial cells
in the transplanted site was decreased in the BMP-2-transplanted group, whereas a high amount of
the cells was observed in the control and FGF-2-transplanted groups at 5 days post-transplantation
(Figure 5B). Next, FCM analysis was performed to calculate the number of CD31+/CD45− endothelial
cells. As a result, after 5 days of transplantation, the number of CD31+/CD45− endothelial cells
in the BMP-2- group and FGF-2-transplanted group showed a decreasing and increasing tendency,
respectively. However, after 14 days, there was no difference in the number of CD31+/CD45− endothelial
cells between the control and experimental groups (Figure 5C).
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2.6. Effects of BMP-2 and FGF-2 on Bone Marrow Cell Populations
Finally, the effect of both BMP-2 and FGF-2 on hematopoietic cell populations were analyzed by
FCM. As shown in Figure 6A,B, bone marrow cellularity did not significantly change by application
of the two growth factors. Note that the FGF-2-transplanted group displayed a significantly lower
amount of T cell population (CD3+) than the group transplanted with the control pellet at 14 days
post-transplantation. However, the percentage of live cells in the hematopoietic stem cell (HSC,
Lin−Sca-1+c-kit+CD150+CD48−), B cell (B220+), erythrocyte (Ter119+) myeloid cell (CD11b+Gr-1+)
populations were not significantly altered either by FGF-2 or BMP-2 (Figure 6A,B). In addition, BMP-2
and FGF-2 induced no significant change in the number of LepR positive stromal cells, which are
known to maintain the hematopoietic stem/progenitor cell niche in the bone marrow (Figure 6A,B).
Together, these results indicate that BMP-2 and FGF-2 have opposing effects on osteoblasts and
osteoclasts in a bone marrow-abundant or scarce environment, but they induce no significant changes
in the hematopoietic cell population or the stem cell niche.
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- (10 µg) or FGF-2 (10 µg) or DW (control) were transplanted int mouse femur defects
and samples were analyzed by FCM at 5 days (A) and 14 d ys (B) after transplantation. H Cs:
Lin−Sca-1+c-Kit+CD150+CD48−, Erythroid cells: Ter119+, Myeloid cells: CD11b+Gr-1+, B cells: B220+,
T cells: CD3+, Leptin R+ stromal cells: CD45−Ter119−CD31−LepR+ (n = 4–11, * p < .05, * p < 0. ,
*** p < 0.001 versus control pellet (#). One-way ANOVA/Tukey).
3. Discussion
Bone regeneration therapy is one of the main topics of concern in regenerative medicine, and,
in recent years, both BMP-2 and FGF-2 have been widely used for alveolar bone regeneration in the
dental field. However, it is still unclear which growth factor should be recommended for alveolar bone
regeneration. Most studies have shown that BMP-2 has a higher osteogenic ability than FGF-2 [16].
Additionally, complications associated with the application of the two growth factors have been
increasingly reported. Therefore, the exact effects of the two growth factors on different cell types,
including not only osteoblasts, osteoclasts but also bone marrow cells, should be investigated in
more detail to promote more effective delivery of FGF-2 and BMP-2 to patients. In the present study,
we evaluated the effects of BMP-2 and FGF-2 on bone formation in bone marrow scarce or abundant
environments and found that BMP-2 had a high bone formation ability in the marrow-scarce calvaria,
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but induced bone resorption in bone marrow-abundant femurs. On the other hand, FGF-2 showed
opposite effects compared to those of BMP-2. Moreover, bone marrow ablation and transplantation
analysis revealed that BMP-2 and FGF-2-induced bone formation was regulated by the bone marrow
cells in the marrow cavity (Figure 3) [25].
In accordance with these findings, we have recently demonstrated that BMP-2 has opposite
functions in inducing, respectively, bone formation or resorption in a bone marrow-scarce or
abundant environment. For instance, BMP-2 was shown to promote bone regeneration and
osteointegration around titanium implants inserted in tooth extraction sockets (extramedullary
environment), but induced bone resorption when the implant was inserted in the mandible marrow.
Moreover, we showed that the BMP-2-induced bone resorption in the femur was regulated by a direct
cell-cell interaction between the marrow cells and osteoblasts in vitro [25].
The results of this study are also in line with those reported by Kawaguchi et al., who showed
that local administration of FGF-2 in long bone fractures, which are bone marrow-abundant sites,
significantly accelerated fracture healing and callus formation [31]. Nagayasu et al. also demonstrated
that local administration of FGF-2 in the bone marrow environment accelerated bone formation around
the dental implant and osteointegration in a dog model [26].
At the cellular level, BMP-2 is known to stimulate the expression of the mineralization-associated
genes but seems to have little or no effect on the expression of genes associated with cell proliferation [32].
FGF-2, on the other hand, seems to have different effects on bone-related cells depending on the cell
differentiation stage. For instance, in mesenchymal progenitor cells, FGF-2 is known to be a strong
inducer of the expression of genes associated with cell proliferation and expression of angiogenic
genes, such as vascular endothelial growth factor A [32,33]. Moreover, the effects of FGF-2 on BMP-2
signaling seem to be dose-dependent; while a low dose of FGF-2 could enhance the BMP-2-associated
bone formation, a high dose of FGF-2 suppressed it. Of note, FGF-2 has been reported to significantly
reduce the expression of BMP-2 and alkaline phosphatase and the mineralization of osteoblasts [32].
FGF-2 also inhibited the phosphorylation of Smad-1 and increased the expression of the BMP-2 inhibitor
Noggin, thus antagonizing the BMP cascade [34,35]. Together, despite the controversies in the literature,
the opposite effects of FGF-2 and BMP-2 observed in the bone marrow-abundant and scarce sites could
be directly or indirectly associated with their antagonistic interactions.
Bone is considered as a rigid organ that supports and protects various vital organs in the body,
including the bone marrow and the stem cell niche [36]. In this context, BMPs are known to play a
fundamental role in the development of hematopoietic bone marrow [37,38]. Devorah et al. reported
that BMP-4, which is also important for both prenatal and post-natal bone formation and regeneration,
is a critical component of the hematopoietic microenvironment that regulates both the number and
function of HSCs [39]. Itkin et al. also reported that systemic administration of FGF-2 regulates
in vivo expansion of both HSCs and their supportive stromal cells, such as CXCL12-abundant reticular
(CAR) cells [40] and LepR positive stromal cells [41,42]. From these reports, we assumed that the
transplantation of BMP-2 and FGF-2 in bone marrow could cause changes in the population of bone
marrow cells. Contrary to our expectations, however, no significant change in the cell population of
murine bone marrow, including LepR positive stromal cell, was observed by local administration of
the two factors, indicating that the local delivery of the two factors is relatively safe. The difference in
the systemic versus local delivery of the growth factors could be a major reason for the discrepancy,
though future studies, for example with different concentrations of the growth factors, are necessary to
clarify these conflicting findings.
In summary, our study demonstrated that BMP-2 and FGF-2 could only induce bone formation,
respectively, in the bone marrow-scarce and abundant environments. Therefore, BMP-2 could be
suitable for application in extramedullary, while the FGF-2, in medullary bone regeneration. Moreover,
both BMP-2 and FGF-2 administrated in the bone marrow did not significantly affect the hematopoietic
cell population, indicating a relatively safe application of the two growth factors. Finally, the two
growth factors could be applied not only in the reconstruction or regeneration of large bone defects
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but also in combination with biomaterials, such as to allow a rapid osteointegration and long-term
stability of implants, which are the key factors for successful functional rehabilitation in dental and
orthopedic treatments.
4. Materials and Methods
4.1. Materials
Recombinant human BMP-2 derived from Escherichia coli was prepared using the methods
reported previously [43,44]. FGF-2 (Fiblast Spray) was purchased from Kaken Pharmaceutical (Tokyo,
Japan). In order to prepare FGF-2 and BMP-2 collagen pellets, 30 µL of atelocollagen (Koken, Tokyo,
Japan) were mixed with BMP-2 (10 µg) or FGF-2 (1 and 10 µg). The control pellet was prepared by
mixing atelocollagen with DW. After mixing, the pellets were frozen at −80 ◦C and dried in vacuum.
The freeze-dried collagen pellets containing the growth factors were transplanted in the bone defects.
4.2. Animal Experiments
Eight-week-old c57BL/6 J mice were purchased from CLEA Japan (Tokyo, Japan). Col1a1(2.3)-GFP
mice [45] and Trap-tdTomato mice [46] were kindly gifted from Dr. Matsuo (Keio University, Tokyo,
Japan) and Dr. Ishii (Osaka University, Osaka, Japan), respectively. For all experiments, mice at
8–12 weeks of age were used. The animal experiment protocol used in this study (OKU-2019254) was
approved by Okayama University Animal Research Committee. All animals were handled according
to the guidelines of the Okayama University Animal Research Committee.
Collagen transplantation into the bone marrow-abundant femoral defect and the bone
marrow-scarce calvarial defect was performed according to our previously reported methods [25].
Briefly, a bone defect was created at a distance of 3 mm above the knee in the mouse both femurs of mice
by a 25-gauge needle and a collagen pellets containing DW (control), BMP-2 or FGF-2 were randomly
transplanted into the marrow cavities of both femurs under general anesthesia. In calvaria, collagen
pellets were transplanted into a 2 mm bone defect made by a biopsy punch (Kai Medical, Tokyo, Japan).
To ablate bone marrow cells, femurs were drilled by a dental reamer and washed out with a phosphate
buffer solution (PBS), and/or further translocated into the dorsal region of recipient mice.
4.3. Micro-CT Analysis
Fourteen days after transplantation, the collected femurs and calvaria were fixed with 4%
paraformaldehyde (PFA) and analyzed by micro-computed tomography (micro-CT, SkyScan 1174,
Aartselaar, Belgium) as described previously [25]. Bone volume/tissue volume (BV/TV) in the femur
was analyzed at an area within 1.5 mm above and below the defect, and the regenerated bone volume
(RBV) in the calvaria was analyzed using SkyScan software (NRecon, CTAn, CTvol, and CTvox,
SkyScan).
4.4. Histological Analysis
Samples decalcified with Morse solution (Shiyaku, Kyoto, Japan) were sectioned and
stained with hematoxylin and eosin (HE). For observation of osteoblast and osteoclast in
Col1a1(2.3)-GFP/TRAP-tdTomato mice and immunohistochemical (IHC) analysis, frozen sections
were prepared by using the Kawamoto’s film method, according to a previous report [47]. For IHC
analysis, sections were blocked with 5% goat serum (Life Technologies, Gaithersburg, MD, USA) for
30 min at room temperature (RT) and incubated with anti-endomucin antibody (EMCN: sc-65495,
Santa Cruz Biotechnology, Dallas, TX, USA) overnight at 4 ◦C. Sections were incubated with the
secondary antibody, Alexa Fluor 647 goat anti-rat IgG (Life Technologies) for 1h at RT in a dark chamber.
All images were taken by a BZ-710 fluorescence microscope (Keyence, Osaka, Japan).
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4.5. Flow Cytometry
For flow cytometric (FCM) analysis, bone marrow cells were flushed out from mouse femur
with PBS containing 2% fetal bovine serum (FBS, 2% FBS/PBS) and gently dissociated by passing the
cells through a 21-gauge needle. Finally, the cells were suspended in 2% FBS/PBS and stained with
fluorescent-labeled antibodies (Table 1). FCM analyses were carried out using the MACSQuant (Miltenyi
Biotec, Bergisch Gladbach, Germany) and data analysis was performed with FlowJo (BD Biosciences,
San Jose, CA, USA). Cell populations were identified as follows: HSC: Lin−Sca-1+c-Kit+CD150+CD48−,
B cell: B220+, T cell: CD3+, Myeloid cell: CD11b+Gr-1+, Erythrocyte: Ter119+, Leptin receptor (LepR)
positive stromal cell: CD45−Ter119−CD31−LepR+, Endothelial cell: CD45−CD31+.
Table 1. Antibodies used for flow cytometry.
Antibody Conjugation Clone Source Cat.#
CD3e APC 145-2C11 BioLegend 100312
CD11b APC M1/70 BioLegend 101212
CD16/32 2.4G2 BD Biosciences 553142
CD31 APC MEC13.3 BioLegend 102509
CD31 PE MEC13.3 BioLegend 102507
CD45 APC 30-F11 BioLegend 103111
CD45R (B220) APC RA3-6B2 BioLegend 103211
CD48 BV421 HM48-1 BioLegend 103428
CD117 (c-Kit) FITC 2B8 BioLegend 105806
CD150 PE TC15-12F12.2 BioLegend 115903
Leptin Receptor Biotin R&D systems BAF497
Lineage marker cocktail APC
145-2C11(CD3e), M1/70(CD11b),
RA3-6B2 (CD45R/B220), TER-119
(Ly76), RB6-8C5 (Ly6G/C)
BD Biosciences 51-9003632
Ly-6A/E (Sca-1) PE-Cy7 D7 BioLegend 108114
Ly-6G/C (Gr-1) BV421 RB6-8C5 BD Biosciences 562709
Streptavidin BV421 BioLegend 405226
Ter119 APC TER-119 BioLegend 116211
7-AAD BioLegend 420404
5. Statistical Analysis
The results obtained from quantitative experiments were reported as the mean values± SD.
Statistical analyses were performed with one-way factorial ANOVA followed by Tukey’s multiple
comparison tests.
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